Nuclear Medicine Radioisotopes Market Growth Through 2030 Creates New Strategic Opportunities
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Nuclear Medicine Radioisotopes Market Forecast: What Market Value Is Expected By 2030?
The nuclear medicine radioisotopes market has experienced significant expansion in recent years, with its value projected to rise from $8.85 billion in 2025 to $9.58 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.2%. This historical growth has been driven by the extensive application of technetium-99m in diagnostic imaging, a surge in nuclear cardiology procedures, a growing incidence of cancer and thyroid disorders, broader establishment of hospital-based nuclear medicine departments, and favorable outcomes from early clinical trials involving radioisotope-based therapies.
The nuclear medicine radioisotopes market is anticipated to experience robust expansion over the coming years, with its value projected to reach $12.75 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.4%. This forecasted growth is driven by several key factors, including the increasing need for personalized cancer treatments, the expanding application of lutetium-177 and actinium-225 therapies, and the enhancement of PET imaging infrastructure. Additional contributors are the rising investments in cyclotron and reactor facilities, along with the growing acceptance of nuclear medicine in emerging economies. Notable trends shaping the forecast period encompass the greater adoption of theranostics in oncology, the surge in demand for PET and SPECT imaging procedures, and the amplified use of targeted alpha and beta emitters. Furthermore, the widening role of nuclear medicine in cardiology and neurology, together with an intensified focus on local radioisotope production, is also shaping the market’s evolution.
Download A Free Sample Report For Comprehensive Market Insights:
Nuclear Medicine Radioisotopes Market Growth Drivers And Industry Catalysts
The escalating prevalence of cardiovascular diseases is anticipated to boost the expansion of the nuclear medicine radioisotope market in the coming period. These diseases encompass disorders affecting the heart and blood vessels. Their increasing frequency stems from sedentary behaviors, unhealthy eating patterns, higher obesity rates, and aging demographics. Radioisotopes used in nuclear medicine are crucial for diagnosing, assessing, and managing heart conditions, offering detailed information on cardiac function, blood flow, and tissue health—vital for precise diagnosis and effective treatment strategies. As of January 2024, the American Heart Association, a nonprofit organization based in the United States, reported that the age-adjusted mortality rate from cardiovascular disease rose to 233.3 per 100,000 individuals, reflecting a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the growing incidence of cardiovascular conditions is fueling demand for nuclear medicine radioisotopes.
Nuclear Medicine Radioisotopes Market Segment Analysis And Revenue Opportunities
The nuclear medicine radioisotopes market covered in this report is segmented –
1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types
2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications
3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users
Subsegments:
1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging
3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)
4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging
5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging
6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment
7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment
8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment
9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)
10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)
Nuclear Medicine Radioisotopes Market Trends Influencing Long-Term Demand
Leading market players in the nuclear medicine radioisotopes sector are concentrating on creating novel approaches, such as next-generation theranostic radiopharmaceuticals, to improve targeted therapy and precise imaging. These advanced radioactive agents are designed to both identify and treat diseases by accurately targeting specific body cells. For example, in November 2025, the University of California, a US-based research institution, established a fully independent Department of Nuclear Medicine & Theranostics, separating it from the broader radiology department. This initiative aims to fast-track the integration of sophisticated imaging with targeted radiopharmaceutical therapies. Additionally, it enhances research, education, and clinical efforts to push precision medicine forward and spur innovations in theranostic treatments.
Nuclear Medicine Radioisotopes Market Leading Players Shaping Industry Direction
Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation
Access The Complete Nuclear Medicine Radioisotopes Market Report:
Nuclear Medicine Radioisotopes Market Regional Analysis And Leading Geography
North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
